LivaNova PLC (LIVN) Stock

LivaNova PLC, a prominent medical device company, specializes in designing, developing, manufacturing, and distributing therapeutic solutions globally. Organized into three core segments Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support the company offers a diverse range of innovative medical products. The Cardiopulmonary segment focuses on oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, and related products crucial for cardiopulmonary care.

In the Neuromodulation sector, LivaNova pioneers the VNS Therapy System, an implantable device delivering vagus nerve stimulation (VNS) therapy. This system targets drug-resistant epilepsy, challenging cases of depression, and obstructive sleep apnea. Additionally, the company is advancing the VITARIA System, currently in development and clinical testing, aimed at treating heart failure through VNS technology.

The Advanced Circulatory Support division specializes in temporary life support solutions, including cardiopulmonary and respiratory support products. These critical technologies cater to medical professionals across various specialties, including perfusionists, neurologists, neurosurgeons, and healthcare institutions worldwide.

Operating through a combination of direct sales teams and independent distributors, LivaNova PLC maintains a strong global presence. The company collaborates extensively in research, notably partnering with Verily to explore clinical biomarkers for depression. Founded in 1987 and headquartered in London, United Kingdom, LivaNova PLC continues to innovate and expand its impact in medical device technologies aimed at improving patient outcomes worldwide.